RAS and BRAF mutational status to patients with metastatic CRC and percentage of patients who received recommended therapy according to the RAS and/or BRAF mutational status. Methods: A descriptive analysis was performed. Indicators were compared
Search Results
Karina Mayra Aliaga, Fradis Gil-Olivares, Laura Pérez, Gisely Hijar, Edward López, Cindy Alcarraz, Mariana Serrano, Claudio Flores, Alonso Díaz, Jose Gutierrez, and Alfredo Aguilar
Krishna Desai, Kristal Pereira, Akhil Jain, Sabah Iqbal, and Rajesh Thirumaran
, fluorouracil, & oxaliplatin) was started, but a new metastatic lesion in the liver was found. In the interim, NGS was positive for IDH-1 & BRAF mutation. Since he was progressing, target therapy with Ivosidenib was added for IDH-1, as per NGS. At 2 year follow
.2011 (Rectal). Based upon recent presentations, the previous footnote related to BRAF mutations was removed and the following footnotes were added to the metastatic section of the NCCN Guidelines for Colon and Rectal Cancers: Footnote in the first
Wells A. Messersmith
the NTRK inhibitor larotrectinib, and some additional language regarding Lynch syndrome and testing, both in terms of expression of the markers and the fact that a BRAF mutation doesn’t rule out Lynch syndrome,” he said at the NCCN 2019 Annual
safety of the orally administered MEK inhibitor trametinib in subjects with melanoma harboring mutations in BRAF at locations other than codon 600 (atypical BRAF mutations; BRAF non-V600MUT) or BRAF fusions. More than 5% of melanomas harbor these
Protocol Chair: Manisha Shah, MD Institutional Principal Investigators: Manisha Shah, MD, and Filip Janku, MD, PhD Condition: Adult malignant tumors with BRAF mutation Institutions: The Ohio State University Comprehensive Cancer Center - James
and safety of the orally administered MEK inhibitor trametinib (GSK1120212) in subjects with melanoma harboring mutations in BRAF at locations other than codon 600 (atypical BRAF mutations; BRAF non-V600 MUT ) or BRAF fusions. More than 5% of
Trametinib (MEKi) in Patients With BRAF Mutation or BRAF Gene Fusion Defect in Thyroid Carcinoma Protocol Chair: Manisha Shah, MD Institutional Principal Investigators: Manisha Shah, MD; Naifa L. Busaidy, MD; Lori Wirth, MD; Jonas DeSouza, MD; and
Mackenzie Taychert, Ankita Aggarwal, David Tabagari, Urja Nagadia, Sai Gajagowni, Venkata Vosuri, and Kushal Naha
Introduction: BRAF mutations in advanced stage colorectal cancers are observed in 8-12% of patients and BRAF V600E is the most frequent alteration. This mutation confers poor prognosis and treatment outcomes with routine systemic chemotherapy
Henry G. Kaplan
tumors Discuss the potential benefits of vemurafenib in the presence of a BRAF mutation Malignant peripheral nerve sheath tumors (MPNSTs) are uncommon cancers that can demonstrate extremely aggressive behavior. Primary treatment involves surgical
